BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zouboulis C, Nogueira da Costa A. Drug repurposing through drug–gene interaction profiles for hidradenitis suppurativa/acne inversa treatment. J Eur Acad Dermatol Venereol 2021;35. [DOI: 10.1111/jdv.16976] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zouboulis VA, Zouboulis KC, Zouboulis CC. Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing-A Molecular Meta-Analysis. Pharmaceutics 2021;14:44. [PMID: 35056940 DOI: 10.3390/pharmaceutics14010044] [Reference Citation Analysis]
2 Cao Y, Hong F, Conlon DM, Sidur L, Smith KM, Fang Y, Cuff CA, Kaymakcalan Z, Ruzek MC. Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa. Br J Dermatol 2021. [PMID: 33811319 DOI: 10.1111/bjd.20097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
3 Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, Jemec GBE, Del Marmol V, Marzano AV, Nikolakis G, Sayed CJ, Tzellos T, Wolk K, Prens EP. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol 2021;30 Suppl 1:8-17. [PMID: 34085329 DOI: 10.1111/exd.14338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
4 Mintoff D, Borg I, Pace NP. The Clinical Relevance of the Microbiome in Hidradenitis Suppurativa: A Systematic Review. Vaccines (Basel) 2021;9:1076. [PMID: 34696185 DOI: 10.3390/vaccines9101076] [Reference Citation Analysis]
5 von Laffert M, Hunger RE, Navarini AA, Zouboulis CC. [Clinical, pathology-associated and molecular biomarkers of hidradenitis suppurativa/acne inversa]. Hautarzt 2021;72:666-75. [PMID: 34213572 DOI: 10.1007/s00105-021-04848-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]